Navigation Links
Johns Hopkins researchers uncover genes at fault for cystic fibrosis-related intestinal obstruction

Researchers at Johns Hopkins have identified a gene that modifies the risk of newborns with cystic fibrosis (CF) developing neonatal intestinal obstruction, a potentially lethal complication of CF. Their findings, which appeared online March 15 in PLoS Genetics, along with the findings of their Toronto-based colleagues, published April 1 in Nature Genetics, may lead to a better understanding of how the intestines work and pave the way for identifying genes involved in secondary complications of other disorders.

Soon after birth, most babies excrete their first stool, a tar-like substance called meconium. But not babies with neonatal intestinal obstruction, or meconium ileus (MI), which affects 15 percent of newborns with CF and, rarely, newborns without CF. Their stool is different.

"It is abnormally viscous due to high protein content and low levels of hydration, and the child can't move it through the intestine," says Garry Cutting, M.D., professor of pediatrics at the Johns Hopkins McKusick-Nathans Institute of Genetic Medicine.

The condition results in death if not treated by surgery or enema. But why some newborns with CF get it and others don't is not well understood. To better understand why this is so and to develop models for finding so-called modifier genesgenes that modify the effects of other genesCutting and his colleagues aimed to figure out which modifier genes contribute to the development of MI. (From their previous work, they already knew that modifier genes contribute to its development.)

Working with Toronto-based collaborators, members of Cutting's team looked for gene variants that occur in CF patients with MI. They knew that CF is caused by disruption of the CFTR gene, which encodes for a cell membrane protein, so they thought that maybe the genes that alter CFTR's activity and cause MI might also encode for cell membrane proteins; after all, a cell membrane protein is more likely to interact with a nearby cell membrane protein than with a protein that's deep inside the cell. They tested DNA samples from 3,763 CF patients611 who had had MI and 3152 who hadn'tto compare genes that encode for cell membrane proteins to those that encode for unrelated proteins. Three of the 155 genes tested that encode for cell membrane proteins correlated with risk for MI, compared with none of the 231 genes tested that encode for unrelated proteins.

"These genes have common variants that all of us happen to be carrying around," says Cutting, "and just by chance, if you have a child with CF, these common variants play a role in modifying risk for meconium ileus." The researchers wanted to look for additional gene variants associated with an increased risk for MI, using a different approach.

In an earlier study, Cutting's team had found a region of human chromosome 8 to be linked to MI. To pinpoint which gene within that region leads to the condition, the researchers analyzed the DNA of 133 families with at least two CF children, at least one of whom previously had MI. The DNA was tested to determine which parts of chromosome 8 parents had passed down to their children who had MI.

Using this approach, the researchers found variants of the methionine sulfoxide reductase (MSRA) genein this case, a particular combination of DNA alterations close to and within the genethat appeared significantly more often in children who had MI. In an unrelated CF patient population from Canada, they found evidence of the same link between MSRA and MI, which helped confirm their results.

While the researchers now knew that CF patients with a certain MSRA gene variant tended to have had MI as newborns, they didn't yet know whether MSRA actually plays a role in MI and hence whether it is truly a modifier gene. To address this question, they turned to mice engineered to have CF that tend to die from intestinal obstruction and developed three genetically modified versions of these mice: one with both MSRA genes intact, one with only one intact, and one with none intact. The fewer the copies of intact MSRA genes, the more likely the mice were to survive. In other words, the loss of MSRA protected the mice from fatal intestinal obstruction.

Cutting and his colleagues don't know how exactly the loss of MSRA reduces risk for fatal intestinal obstruction, but they suspect that MSRA's ability to alter the activity of specific intestinal enzymes may be the key. They suspect that with reduced levels of MSRA, the enzymes are free to do their job breaking down proteins that make up meconium so that meconium can pass through the intestines and be evacuated normally at birth.

The researchers' work on MSRA could shed light on how meconium normally gets broken down in the intestines. Moreover, use of the techniques pioneered by Cutting and his colleagues may lead to identification of modifier genes that play roles in other complications of CF, like lung function, and in other diseases caused by a single gene, like Huntington's disease.


Contact: Audrey Huang
Johns Hopkins Medical Institutions

Related biology news :

1. BGI announces collaboration with Johns Hopkins University on synthetic yeast project
2. NIH Directors Awards go to 3 Johns Hopkins scientists
3. Johns Hopkins researchers identify new genetic risk factor for sudden cardiac death
4. Johns Hopkins researchers awarded $32 million
5. Johns Hopkins scientists expose cancer cells universal dark matter
6. Johns Hopkins researchers link cell division and oxygen levels
7. Johns Hopkins scientists reveal nerve cells navigation system
8. Texas researcher Arthur E. Johnson to give prestigious ASBMB-Lipmann Lectureship
9. Johns Hopkins team creates stem cells from schizophrenia patients
10. Johns Hopkins researchers capture jumping genes
11. Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow
Post Your Comments:
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
Breaking Biology Technology: